Clal Biotechnology Industries Ltd. (CBI.TA)
ILA 35.6
(-0.84%)
ILA 35.6
(-0.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 36.97 Million ILS | -2.16% |
| 2022 | 37.79 Million ILS | -64.53% |
| 2021 | 106.54 Million ILS | 6.29% |
| 2020 | 100.24 Million ILS | -15.85% |
| 2019 | 119.11 Million ILS | -19.76% |
| 2018 | 148.46 Million ILS | -34.35% |
| 2017 | 226.14 Million ILS | -38.25% |
| 2016 | 366.21 Million ILS | -16.83% |
| 2015 | 440.3 Million ILS | 2.77% |
| 2014 | 428.44 Million ILS | -20.72% |
| 2013 | 540.45 Million ILS | 52.59% |
| 2012 | 354.19 Million ILS | 149.42% |
| 2011 | 142 Million ILS | 2.75% |
| 2010 | 138.2 Million ILS | -9.91% |
| 2009 | 153.4 Million ILS | 1.28% |
| 2008 | 151.46 Million ILS | 36.48% |
| 2007 | 110.98 Million ILS | 787.86% |
| 2006 | 12.5 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 36.97 Million ILS | -9.79% |
| 2023 FY | 36.97 Million ILS | -2.16% |
| 2023 Q2 | 40.98 Million ILS | 0.0% |
| 2023 Q4 | 36.97 Million ILS | 0.0% |
| 2023 Q1 | 40.98 Million ILS | 8.46% |
| 2022 Q4 | 37.79 Million ILS | -1.04% |
| 2022 Q1 | 109.14 Million ILS | 2.44% |
| 2022 FY | 37.79 Million ILS | -64.53% |
| 2022 Q2 | 115.05 Million ILS | 5.41% |
| 2022 Q3 | 38.18 Million ILS | -66.81% |
| 2021 FY | 106.54 Million ILS | 6.29% |
| 2021 Q2 | 109.62 Million ILS | -24.74% |
| 2021 Q3 | 111.64 Million ILS | 1.84% |
| 2021 Q4 | 106.54 Million ILS | -4.56% |
| 2021 Q1 | 145.65 Million ILS | 45.31% |
| 2020 Q4 | 100.24 Million ILS | -17.48% |
| 2020 FY | 100.24 Million ILS | -15.85% |
| 2020 Q1 | 118.79 Million ILS | -0.27% |
| 2020 Q2 | 114.35 Million ILS | -3.74% |
| 2020 Q3 | 121.47 Million ILS | 6.23% |
| 2019 Q3 | 117.74 Million ILS | -11.9% |
| 2019 FY | 119.11 Million ILS | -19.76% |
| 2019 Q4 | 119.11 Million ILS | 1.17% |
| 2019 Q1 | 155.29 Million ILS | 4.6% |
| 2019 Q2 | 133.65 Million ILS | -13.93% |
| 2018 FY | 148.46 Million ILS | -34.35% |
| 2018 Q4 | 148.46 Million ILS | -20.13% |
| 2018 Q3 | 185.87 Million ILS | -8.37% |
| 2018 Q2 | 202.85 Million ILS | -12.51% |
| 2018 Q1 | 231.87 Million ILS | 2.53% |
| 2017 Q1 | 335.47 Million ILS | -8.4% |
| 2017 Q4 | 226.14 Million ILS | -7.58% |
| 2017 Q3 | 244.7 Million ILS | -21.83% |
| 2017 FY | 226.14 Million ILS | -38.25% |
| 2017 Q2 | 313.04 Million ILS | -6.68% |
| 2016 Q3 | 389.16 Million ILS | -5.39% |
| 2016 FY | 366.21 Million ILS | -16.83% |
| 2016 Q2 | 411.33 Million ILS | 4.82% |
| 2016 Q4 | 366.21 Million ILS | -5.9% |
| 2016 Q1 | 392.41 Million ILS | -10.88% |
| 2015 Q1 | 439.17 Million ILS | 2.5% |
| 2015 FY | 440.3 Million ILS | 2.77% |
| 2015 Q4 | 440.3 Million ILS | 6.89% |
| 2015 Q3 | 411.92 Million ILS | 3.7% |
| 2015 Q2 | 397.21 Million ILS | -9.55% |
| 2014 Q2 | 425.39 Million ILS | -11.48% |
| 2014 FY | 428.44 Million ILS | -20.72% |
| 2014 Q1 | 480.57 Million ILS | -11.08% |
| 2014 Q4 | 428.44 Million ILS | 0.73% |
| 2014 Q3 | 425.34 Million ILS | -0.01% |
| 2013 Q1 | 482.12 Million ILS | 36.12% |
| 2013 Q2 | 495.27 Million ILS | 2.73% |
| 2013 Q3 | 604.13 Million ILS | 21.98% |
| 2013 FY | 540.45 Million ILS | 52.59% |
| 2013 Q4 | 540.45 Million ILS | -10.54% |
| 2012 Q4 | 354.19 Million ILS | 0.0% |
| 2012 FY | 354.19 Million ILS | 149.42% |
| 2011 FY | 142 Million ILS | 2.75% |
| 2010 FY | 138.2 Million ILS | -9.91% |
| 2009 FY | 153.4 Million ILS | 1.28% |
| 2008 FY | 151.46 Million ILS | 36.48% |
| 2007 FY | 110.98 Million ILS | 787.86% |
| 2006 FY | 12.5 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Matricelf Ltd | 3.7 Million ILA | -899.405% |